ÂÜÀòÂÒÂ×

Sapan Shah, PhD, is an accomplished biotechnology executive with extensive experience in leading innovative therapeutic advancements. Currently serving as the Chief Executive Officer of Glyscend Therapeutics, Sapan is at the forefront of developing first-in-class oral polymer medicines to address metabolic diseases. Sapan also founded and leads Novatherx, LLC, providing strategic guidance to biotech and pharmaceutical companies. Additionally, Sapan contributes as an Entrepreneur In Residence at Yale Ventures and previously held CEO roles at StrideBio and ARMGO Pharma. Sapan's early career includes advisory positions for startups like Neochromosome and Allyx Therapeutics, along with significant leadership within organizations such as NewYorkBIO and the New York Pharma Forum. Sapan holds a PhD and M.Phil. in Molecular Biophysics and Biochemistry from Yale University and a BA in Mathematics and Biochemistry from Northwestern University.